Inhibrx Biosciences Inc (INBX)

Apr 1, 2025, 4:05 PM EDT - 6 days ago

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Mar 17, 2025, 4:05 PM EDT - 21 days ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Jan 21, 2025, 5:01 PM EST - 2 months ago

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Jan 13, 2025, 4:15 PM EST - 3 months ago

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Nov 14, 2024, 4:24 PM EST - 5 months ago

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 11:45 AM EST - 5 months ago

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Nov 4, 2024, 4:00 PM EST - 5 months ago

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Aug 27, 2024, 7:10 AM EDT - 7 months ago

Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying

HNRG TCBI

Aug 13, 2024, 6:54 PM EDT - 8 months ago

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Jun 7, 2024, 2:42 PM EDT - 10 months ago

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Jun 5, 2024, 7:46 AM EDT - 10 months ago

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)

A EXAS TDOC

May 24, 2024, 4:00 PM EDT - 11 months ago

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

May 10, 2024, 6:36 PM EDT - 11 months ago

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

May 9, 2024, 3:36 PM EDT - 11 months ago

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

SNY

May 8, 2024, 4:37 PM EDT - 11 months ago

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Feb 28, 2024, 9:15 AM EST - 1 year ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Jan 23, 2024, 11:45 AM EST - 1 year ago

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

SNY

Jan 23, 2024, 5:39 AM EST - 1 year ago

Sanofi to Buy Rare-Disease Assets From Inhibrx

SNY

Jan 23, 2024, 1:32 AM EST - 1 year ago

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

SNY

Jan 23, 2024, 1:30 AM EST - 1 year ago

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

SNY

Jan 23, 2024, 1:00 AM EST - 1 year ago

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

SNY

Nov 9, 2023, 4:00 PM EST - 1 year ago

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:15 AM EDT - 1 year ago

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Oct 18, 2023, 4:00 PM EDT - 1 year ago

Inhibrx Announces Participation in Upcoming Scientific Conferences

Sep 19, 2023, 4:00 PM EDT - 1 year ago

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Sep 1, 2023, 4:26 PM EDT - 1 year ago

Andreas Halvorsen's Firm Ups Inhibrx Stake

Aug 29, 2023, 9:00 AM EDT - 1 year ago

Inhibrx Announces $200 Million Private Placement Financing

Aug 17, 2023, 4:41 PM EDT - 1 year ago

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

Aug 7, 2023, 4:00 PM EDT - 1 year ago

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

May 30, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 8, 2023, 4:05 PM EDT - 2 years ago

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Apr 26, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Apr 13, 2023, 11:12 AM EDT - 2 years ago

Inhibrx: Undercovered Company With Good Potential

Mar 6, 2023, 4:05 PM EST - 2 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Jan 4, 2023, 9:00 AM EST - 2 years ago

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

Nov 18, 2022, 4:05 PM EST - 2 years ago

Inhibrx Announces Participation in Upcoming Investor Conference

Nov 16, 2022, 9:00 AM EST - 2 years ago

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

Nov 7, 2022, 4:05 PM EST - 2 years ago

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Oct 4, 2022, 8:00 AM EDT - 2 years ago

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Oct 3, 2022, 4:30 PM EDT - 2 years ago

Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

Aug 15, 2022, 4:05 PM EDT - 2 years ago

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

Aug 8, 2022, 5:19 PM EDT - 2 years ago

Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Jun 30, 2022, 9:00 AM EDT - 3 years ago

Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance

Jun 10, 2022, 1:29 PM EDT - 3 years ago

Inhibrx: Potential To Move To Registration Study With INBRX-101

May 19, 2022, 4:05 PM EDT - 3 years ago

Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting

May 16, 2022, 12:42 PM EDT - 3 years ago

Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder

May 16, 2022, 9:00 AM EDT - 3 years ago

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

May 9, 2022, 4:05 PM EDT - 3 years ago

Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights